Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy. BioWorld Science Neurology/psychiatric Patents Popular ...

W. Joseph Herring, MD, PhD, from Merck Sharp & Dohme in Whitehouse Station, NJ, and colleagues randomly assigned 254 healthy adults with primary insomnia to placebo or suvorexant (10mg, 20mg, 40mg ...

Committee members deem newly developed selective antagonist of orexin receptors effective but expressed concern about somnolence and driving safety for higher doses. ... Merck Sharp & Dohme Corp.) ...

Merck & Co. is a global marketer of prescription medicines, vaccines and animal health products. Merck is known as MSD (Merck Sharp & Dohme) outside the United States and Canada. Featured Stories.

Article ‘Count’ and ‘Share’ for Merck Sharp and Dohme AG (MSD Switzerland) based on listed parameters only. The articles listed below published by authors from Merck Sharp and Dohme AG ...

Merck Sharp & Dohme’s sotatercept gets UK MHRA marketing approval to treat adult patients with pulmonary arterial hypertension: United Kingdom Friday, January 3, 2025, 17:00 Hrs [IST] The UK Medicines ...

WESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy ...

TT-816 is a first-in-class, oral cannabinoid CB 2 receptor antagonist acting as a novel immune response modifier for the treatment of a broad range of solid tumors and is highly selective for the ...

Targeting the androgen receptor by depriving testosterone with gonadotropin-releasing hormone agonists or antagonists, or surgical castration, has been the backbone of metastatic prostate cancer ...

Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy. BioWorld Science Neurology/psychiatric Patents Popular ...

Merck Sharp and Dohme AG (MSD Switzerland), Switzerland Time frame: 1 February 2023 - 31 January 2024 Research. Overall research output. Count ...